Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
Entera Bio Ltd. announced robust preclinical results for EB612, an oral long-acting PTH(1-34) peptide for hypoparathyroidism, and EB618, an oral dual GLP-1/glucagon receptor agonist for obesity and metabolic disorders. Both candidates showed favorable pharmacokinetics, sustained therapeutic effects, and good tolerability in multiple preclinical mod…